ArticleEuropean thyroid journal2021

Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer.

Laura Valerio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.